Mauro Libi Crestani

Inspira™ Technologies Reveals Next Generation Liby™ System, an Extracorporeal Membrane Oxygenation System, Targeting a $531 Million Global ECMO Market

Retrieved on: 
Monday, July 11, 2022

The Liby System is intended to target the $531million global ECMO market.

Key Points: 
  • The Liby System is intended to target the $531million global ECMO market.
  • The Inspira Technologies Liby system currently under development, is expected to be submitted to the U.S. Food and Drug Administration (FDA) for approval, during the first half of 2023.
  • The Inspira Technologies Liby system is designed to be a new generation ECMO system, with potential advantages that may improve usability and patient care.
  • Dagi Ben-Noon, Inspira Technologies' Chief Executive Officer, stated:
    "The Liby system is intended to target one of three market segments within Inspira Technologies product scope.

Inspira™ Technologies Reveals Next Generation Liby™ ECMO, an Extracorporeal Membrane Oxygenation System, Targeting a $531 Million Global ECMO Market

Retrieved on: 
Monday, July 11, 2022

The Liby System is intended to target the $531million global ECMO market.

Key Points: 
  • The Liby System is intended to target the $531million global ECMO market.
  • The Inspira Technologies Liby system currently under development, is expected to be submitted to the U.S. Food and Drug Administration (FDA) for approval, during the first half of 2023.
  • The Inspira Technologies Liby system is designed to be a new generation ECMO system, with potential advantages that may improve usability and patient care.
  • Dagi Ben-Noon, Inspira Technologies' Chief Executive Officer, stated:
    "The Liby system is intended to target one of three market segments within Inspira Technologies product scope.